Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01072565 · ClinicalTrials.gov registry record · NA
Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring
A NA study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- NA
- Development phase
- 91
- Enrollment target
NCT01072565: Completed NA study, sponsored by HealthPartners Institute.
NCT01072565 is a NA study that has completed, run by HealthPartners Institute. The registered enrollment target is 91 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01072565, a NA study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 91 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of Self Monitoring of Blood Glucose (SMBG) for clinical decisions related to the management of type 2 diabetes and to determine the benefit of using Continuous Glucose Monitoring (CGM) for clinical diabetes management.
Interventions
- OTHER SMBG to guide clinical decisions
- OTHER SMBG and CGM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-01 |
| Phase | NA |
What the finished NCT01072565 record still lists
NCT01072565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which SMBG to guide clinical decisions is the first listed.
NCT01072565 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01072565 about?
NCT01072565 is a clinical study titled "Modal Day Analysis of Self Monitoring Blood Glucose Versus Continuous Glucose Monitoring". The purpose of this study is to evaluate the effectiveness of Self Monitoring of Blood Glucose (SMBG) for clinical decisions related to the management of type 2 diabetes and to determine the benefit of using Continuous Glucose Monitoring (CGM) for clinical diabetes management.
What is the current status of trial NCT01072565?
This trial is currently completed. It is a NA study. The enrollment target is 91 participants. The study started on 2010-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01072565?
The interventions under investigation include: SMBG to guide clinical decisions (OTHER), SMBG and CGM (OTHER).
Who is sponsoring clinical trial NCT01072565?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01072565's enrollment target sits among peer trials
91 939th of 2000 higher than 1,060 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia